The Global In Vitro Diagnostics Market is estimated to garner US$ 85.23 billion by 2027, registering a CAGR of 5% during the forecast period 2020-2027.
 |
Precedence Research, Recently Published Report on “In Vitro Diagnostics Market Size, Share, Growth, Trends, Segment Forecasts, Regional Outlook 2020 - 2027”. The report offers an up-to-date analysis regarding the current market scenario, latest trends, key drivers, potential challenges, profitability graph and the overall market environment.
In vitro diagnostics are medical devices that are diagnoses a medical condition using assays and reagents. Tests can be performed on tissue or blood taken from human body. IVD become essential tool in order to diagnose and identify diseases plus offers projection and forecasting treatment response in clinical practice. Various in vitro diagnostics techniques available at present include hematology, immunodiagnostics, molecular diagnostics and tissue diagnostics. In vitro diagnostic can also be utilized to check a person’s health condition and offer them preventive measures. These IVDs may include next generation tests which require scanning persons DNA to detect genomic variations. Increasing demand for self-tests and point-of-care is projected to accelerate the growth of IVD treatments. Point-of-care testing segment of IVD market is growing rapidly as healthcare systems increasing their reliance on these technologies for informed patient care decisions with easy-to-use tests that offer speed and accuracy.
Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1130
Development in molecular diagnostics and growing adoption of precision medicine has extended in vitro diagnostics application areas in modern medicine. Additionally, diagnostics center invests enough amounts on Research and Development. For instance, in 2018, players such as Roche, Sysmex and bioMerieuxspent around USD 1.4 billion, USD 158 million and USD 326 million respectively on R&D activities.
Report Highlights
- Existence of research organizations that offer clinical research, consulting services, and laboratory testing to cater the swelling demand for rapid diagnosis and treatment plans is likely to fuel the IVD market.
- The growth of the IVD market is attributed to increasing geriatric population and rapid prevalence of acute and chronic diseases.
- The in vitro diagnostic may include next generation sequencing tests which diagnoses persons DNA to catch genomic variations.
- Emerging economies are predicted to offer lucrative opportunities for key players in the IVD market.
Growth Factors
The in vitro diagnostics market is expected to grow at a CAGR of around 5% over the forecast period and the market growth is majorly driven by increasing geriatric population. United Nations forecasted there were around 962 million people with age beyond 60 years in 2017. Further, substantial growth in the prevalence of acute as well as chronic diseases, growing adoption of automatic means and automation in laboratories will drive the IVD market. Growth in the condition specific tests increases significance for IVD tests in developing countries such as India and China which in turn propel the opportunities for key players in the market. Major factors driving the growth are technological advancement as well as focus of key players on constant introduction of innovative products. In addition, availability of Medicaid and Medicare facilities owing to increasing demand for disease diagnosis using IVD is projected to fuel growth in the IVD market over the forecast period. However, rigorous government regulations and adverse reimbursement policy may hinder the IVD market growth. Nonetheless, developing economies offers lucrative growth opportunities for manufacturers involved in the in vitro diagnostics market.
Increasing global spending on healthcare owing to increasing geriatric population and growing adoption of treatments and continuous advancements in technology is expected to propel the in vitro diagnostics market growth in the near future. However, the growth in developed market is predicted to remain steady whereas Asia Pacific and other developing markets will lead the in vitro diagnostics market over the forecast period.
Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1130
Regional Snapshot
North American led to in vitro diagnostics market in 2019, owing to supportive government regulations, leading healthcare infrastructure and advancements into in vitro diagnostics system. In addition, owing to increasing awareness regarding viral disease detection and development of in vitro diagnostics kits for hospital labs is expected to drive the market growth in North America. For example, Lexent Bio entered partnership with Illuminia, Inc. in order to develop an IVD in vitro diagnostic kit for product offering of next generation sequencing based cancer diagnostics. On the other hand, Asia Pacific is anticipated to witness highest CAGR during the estimated time. Huge target population and upgrading healthcare infrastructure boosts the growth of IVD market in the region.
Key Players & Strategies
The in vitro diagnostics market is intensively competitive with presence of a large number of emerging players. The key market players include Alere, Inc., Hoffmann-La Roche Ltd., Arkray, Beckman coulter and many others. Major players in the market are developing innovative products and planning strategic initiatives, like mergers, acquisitions and collaborations in order to acquire significant market share and extend their product range. For instance, in 2018, Roche Diagnostics dominated the industry and revenues were double that of its competitors in the same year. Abbott Diagnostics acquired Alere and firmly held the second position in revenue. This acquisition led Abbott as the leader in point of care testing across the globe.
Market Segmentation
By Product
- Reagents
- Instruments
- Services
By Technology
- Hematology
- Reagents
- Instruments
- Service
- Molecular Diagnostics
- Reagents
- Instruments
- Services
- Immunology
- Reagents
- Instruments
- Services
- Coagulation
- Reagents
- Instruments
- Services
- Clinical Chemistry
- Reagents
- Instruments
- Services
- Microbiology
- Reagents
- Instruments
- Services
- Others
- Reagents
- Instruments
- Services
By Application
- Diabetes
- Cardiology
- Nephrology
- Infectious Disease
- Oncology
- Drug Testing
- Autoimmune Diseases
- Others
By Regional
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Middle East & Africa
- Latin America
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. In Vitro Diagnostics (IVD) Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
Chapter 5. COVID 19 Impact on In Vitro Diagnostics (IVD) Market
5.1. Covid-19: In Vitro Diagnostics (IVD) Industry Impact
5.2. In Vitro Diagnostics (IVD) Business Impact Assessment: Covid-19
5.2.1. Supply Chain Challenges/Disruption
5.2.2. Market Trends and In Vitro Diagnostics (IVD) Opportunities in the COVID-19 Landscape
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for In Vitro Diagnostics (IVD) Manufacturers to deal with Covid-19 Pandemic Scenario
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Global In Vitro Diagnostics (IVD) Market: Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. In Vitro Diagnostics (IVD) Market Revenue by Manufacturer (2015-2020)
7.1.1.2. In Vitro Diagnostics (IVD) Market Revenue Market Share by Manufacturer (2015-2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Capacity Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global In Vitro Diagnostics (IVD) Market, By Product Type
8.1. In Vitro Diagnostics (IVD) Market, by Product Type, 2016-2027
8.1.1. Reagents
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Instruments
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global In Vitro Diagnostics (IVD) Market, By Technology
9.1. In Vitro Diagnostics (IVD) Market, By Technology, 2016-2027
9.1.1. Hematology
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Molecular Diagnostics
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Immunology
9.1.3.1. Market Revenue and Forecast (2016-2027)
9.1.4. Coagulation
9.1.4.1. Market Revenue and Forecast (2016-2027)
9.1.5. Clinical Chemistry
9.1.5.1. Market Revenue and Forecast (2016-2027)
9.1.6. Microbiology
9.1.6.1. Market Revenue and Forecast (2016-2027)
9.1.7. Other
9.1.7.1. Market Revenue and Forecast (2016-2027)
Chapter 10. Global In Vitro Diagnostics (IVD) Market, By Application
10.1. In Vitro Diagnostics (IVD) Market, By Application, 2016-2027
10.1.1. Diabetes
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Cardiology
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Nephrology
10.1.3.1. Market Revenue and Forecast (2016-2027)
10.1.4. Infectious Disease
10.1.4.1. Market Revenue and Forecast (2016-2027)
10.1.5. Oncology
10.1.5.1. Market Revenue and Forecast (2016-2027)
10.1.6. Drug Testing
10.1.6.1. Market Revenue and Forecast (2016-2027)
10.1.7. Autoimmune Diseases
10.1.7.1. Market Revenue and Forecast (2016-2027)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2016-2027)
Chapter 11. Global In Vitro Diagnostics (IVD) Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue Forecast by Product (2016-2027)
11.1.2. Market Revenue Forecast By Technology (2016-2027)
11.1.3. Market Revenue Forecast By Application (2016-2027)
11.1.4. Market Revenue Forecast by Technology (2016-2027)
11.1.5. U.S
11.1.5.1. Market Revenue Forecast (2016-2027)
11.1.5.2. Market Revenue Forecast (2016-2027)
11.1.6. Canada
11.1.6.1. Market Revenue Forecast (2016-2027)
11.1.6.2. Market Revenue Forecast (2016-2027)
11.2. Europe
11.2.1. Market Revenue Forecast by Product (2016-2027)
11.2.2. Market Revenue Forecast By Technology (2016-2027)
11.2.3. Market Revenue Forecast By Application (2016-2027)
11.2.4. Market Revenue Forecast by Technology (2016-2027)
11.2.5. UK
11.2.5.1. Market Revenue Forecast (2016-2027)
11.2.5.2. Market Revenue Forecast (2016-2027)
11.2.6. Germany
11.2.6.1. Market Revenue Forecast (2016-2027)
11.2.6.2. Market Revenue Forecast (2016-2027)
11.2.7. France
11.2.7.1. Market Revenue Forecast (2016-2027)
11.2.7.2. Market Revenue Forecast (2016-2027)
11.2.8. Rest of EU
11.2.8.1. Market Revenue Forecast (2016-2027)
11.2.8.2. Market Revenue Forecast (2016-2027)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Product (2016-2027)
11.3.2. Market Revenue Forecast By Technology (2016-2027)
11.3.3. Market Revenue Forecast By Application (2016-2027)
11.3.4. Market Revenue Forecast by Technology (2016-2027)
11.3.5. China
11.3.5.1. Market Revenue Forecast (2016-2027)
11.3.5.2. Market Revenue Forecast (2016-2027)
11.3.6. India
11.3.6.1. Market Revenue Forecast (2016-2027)
11.3.6.2. Market Revenue Forecast (2016-2027)
11.3.7. Japan
11.3.7.1. Market Revenue Forecast (2016-2027)
11.3.7.2. Market Revenue Forecast (2016-2027)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue Forecast (2016-2027)
11.3.8.2. Market Revenue Forecast (2016-2027)
11.4. LATAM
11.4.1. Market Revenue Forecast by Product (2016-2027)
11.4.2. Market Revenue Forecast By Technology (2016-2027)
11.4.3. Market Revenue Forecast By Application (2016-2027)
11.4.4. Market Revenue Forecast by Technology (2016-2027)
11.4.5. Brazil
11.4.5.1. Market Revenue Forecast (2016-2027)
11.4.5.2. Market Revenue Forecast (2016-2027)
11.4.6. Rest of LATAM
11.4.6.1. Market Revenue Forecast (2016-2027)
11.4.6.2. Market Revenue Forecast (2016-2027)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Product (2016-2027)
11.5.2. Market Revenue Forecast By Technology (2016-2027)
11.5.3. Market Revenue Forecast By Application (2016-2027)
11.5.4. Market Revenue Forecast by Technology (2016-2027)
11.5.5. GCC
11.5.5.1. Market Revenue Forecast (2016-2027)
11.5.5.2. Market Revenue Forecast (2016-2027)
11.5.6. North Africa
11.5.6.1. Market Revenue Forecast (2016-2027)
11.5.6.2. Market Revenue Forecast (2016-2027)
11.5.7. South Africa
11.5.7.1. Market Revenue Forecast (2016-2027)
11.5.7.2. Market Revenue Forecast (2016-2027)
11.5.8. Rest of MEA
11.5.8.1. Market Revenue Forecast (2016-2027)
11.5.8.2. Market Revenue Forecast (2016-2027)
Chapter 12. Company Profiles
12.1.1. Company Overview, Business Information, Manufacturing Area
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Application
12.1.3. Revenue and Gross Margin (2015-2020)
12.1.4. Recent Developments and Strategies
12.2. Hoffmann-La Roche Ltd.
12.2.1. Company Overview, Business Information, Manufacturing Area
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Application
12.2.3. Revenue and Gross Margin (2015-2020)
12.2.4. Recent Developments and Strategies
12.3. Arkray
12.3.1. Company Overview, Business Information, Manufacturing Area
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Application
12.3.3. Revenue and Gross Margin (2015-2020)
12.3.4. Recent Developments and Strategies
12.4. Beckman Coulter
12.4.1. Company Overview, Business Information, Manufacturing Area
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Application
12.4.3. Revenue and Gross Margin (2015-2020)
12.4.4. Recent Developments and Strategies
12.5. Becton Disckinson
12.5.1. Company Overview, Business Information, Manufacturing Area
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Application
12.5.3. Revenue and Gross Margin (2015-2020)
12.5.4. Recent Developments and Strategies
12.6. Bio-Rad laboratories
12.6.1. Company Overview, Business Information, Manufacturing Area
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Application
12.6.3. Revenue and Gross Margin (2015-2020)
12.6.4. Recent Developments and Strategies
12.7. bioMerieux S.A.
12.7.1. Company Overview, Business Information, Manufacturing Area
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Application
12.7.3. Revenue and Gross Margin (2015-2020)
12.7.4. Recent Developments and Strategies
12.8. Danaher
12.8.1. Company Overview, Business Information, Manufacturing Area
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Application
12.8.3. Revenue and Gross Margin (2015-2020)
12.8.4. Recent Developments and Strategies
12.9. Sysmex Corporation
12.9.1. Company Overview, Business Information, Manufacturing Area
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Application
12.9.3. Revenue and Gross Margin (2015-2020)
12.9.4. Recent Developments and Strategies
12.10. Abbott Laboratories
12.10.1. Company Overview, Business Information, Manufacturing Area
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Application
12.10.3. Revenue and Gross Margin (2015-2020)
12.10.4. Recent Developments and Strategies
12.11. Company 11
12.11.1. Company Overview, Business Information, Manufacturing Area
12.11.2. Product Portfolio Analysis
12.11.2.1. Product Details, Specification, Application
12.11.3. Revenue and Gross Margin (2015-2020)
12.11.4. Recent Developments and Strategies
12.12. Company 12
12.12.1. Company Overview, Business Information, Manufacturing Area
12.12.2. Product Portfolio Analysis
12.12.2.1. Product Details, Specification, Application
12.12.3. Revenue and Gross Margin (2015-2020)
12.12.4. Recent Developments and Strategies
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1130
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 774 402 6168
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
0 Comments